<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02438813</url>
  </required_header>
  <id_info>
    <org_study_id>CONTOUR</org_study_id>
    <nct_id>NCT02438813</nct_id>
  </id_info>
  <brief_title>Condition of Submental Fullness and Treatment Outcomes Registry</brief_title>
  <acronym>CONTOUR</acronym>
  <official_title>CONTOUR: Condition of Submental Fullness and Treatment Outcomes Registry (A Registry of Submental Fullness, Treatment Options Administered, and Associated Outcomes)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kythera Biopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kythera Biopharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this registry is to develop a comprehensive understanding of the
      condition of submental (SM) fullness due to submental fat (SMF), how it is treated in current
      clinical practice, and the risks and benefits associated with its treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 11, 2015</start_date>
  <completion_date type="Actual">November 10, 2016</completion_date>
  <primary_completion_date type="Actual">November 10, 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Weeks</target_duration>
  <primary_outcome>
    <measure>Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)</measure>
    <time_frame>Up to 19 Months</time_frame>
    <description>An adverse event is any undesirable medical occurrence or worsening of an existing condition that occurs after SMF reduction treatment, irrespective of whether the event is considered treatment related. A treatment-emergent adverse event is defined as an adverse event with an onset that occurs after receiving treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)</measure>
    <time_frame>Baseline (Day 1) to the Follow-up Visit (Up to 9 Months) and Baseline to End of Treatment (EOT) Visit (Up to 18 Months)</time_frame>
    <description>The CR-SMFRS is based on the investigator's clinical evaluation of the participant's chin and neck area using a 5-point ordinal scale (0 to 4) with 0=Absent Submental Convexity: no localized submental fat evident; 1=Mild Submental Convexity: minimal, localized submental fat; 2=Moderate Submental Convexity: prominent, localized submental fat; 3=Severe Submental Convexity; a marked amount of chin fat; and 4=Extreme Submental Convexity: marked, localized submental fat. A negative change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient-Reported Submental Fat Rating Scale (PR-SMFRS)</measure>
    <time_frame>Baseline (Day 1) to the Follow-up Visit (Up to 9 Months) and Baseline to End of Treatment Visit (Up to 18 Months)</time_frame>
    <description>The PR-SMFRS is based on the participant's response to the question &quot;How much fat do you have under your chin right now?&quot; answered on a 5-point ordinal scale (0 to 4) with 0=No chin fat at all, 1=A slight amount of chin fat, 2=A moderate amount of chin fat, 3=A large amount of chin fat, and 4=A very large amount of chin fat. A negative change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Patient-Reported Submental Fat Impact Scale (PR-SMFIS)</measure>
    <time_frame>Baseline (Day 1) to the Follow-up Visit (Up to 9 Months) and Baseline to End of Treatment Visit (Up to 18 Months)</time_frame>
    <description>The PR-SMFIS assesses the impact of submental fat on self-perception of 6 emotional and visual characteristics related to the appearance of submental fullness (unhappy, bothered, self-conscious, embarrassed, look older, and look overweight) as evaluated by the participant. Each item is rated on an 11-point numeric scale from 0 to 10. Scores for the 6 items were averaged to generate a PR-SMFIS total scale score ranging from 0 to 10 where 0 is a positive outcome and 10 is a negative outcome. A negative change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Subject Self Rating Scale (SSRS)</measure>
    <time_frame>Baseline (Day 1) to the Follow-up Visit (Up to 9 Months) and Baseline to End of Treatment Visit (Up to 18 Months)</time_frame>
    <description>The participant was asked to answer the question: &quot;Considering your appearance in association with your face and chin, how satisfied do you feel with your appearance at the present time?&quot; using a 7-point scale: 0=Extremely dissatisfied, 1=Dissatisfied, 2=Slightly dissatisfied, 3=neither satisfied nor dissatisfied, 4=Slightly satisfied, 5=Satisfied, and 6=Extremely satisfied. A positive change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Patient Self-Perception of Age (SPA)</measure>
    <time_frame>Baseline (Day 1) to End of Treatment Visit (Up to 18 Months)</time_frame>
    <description>The participant rated their facial age in years at Baseline and at the End of Treatment Visit by answering the question: How many years difference compare to your actual age? A negative number indicates younger and a positive number indicates older. A negative change from Baseline indicates an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Submental Skin Laxity Scale (SMSLG)</measure>
    <time_frame>Baseline (Day 1) to the Follow-up Visit (Up to 9 Months) and Baseline to End of Treatment Visit (Up to 18 Months)</time_frame>
    <description>SMSLG assessment was based on clinical evaluation and palpation of the submental area. The SMSLG scale incorporates 3 features: skin wrinkling, adherence to underlying neck structures (bone and muscle) and redundancy (horizontal and vertical folds).
Grade 1 (none): no or minimal superficial wrinkling, skin well apposed to deeper neck structures, no skin redundancy [no skin draping or skin sagging]; Grade 2 (mild): mild superficial wrinkling, skin well apposed to deeper neck structures, minimal skin redundancy [slight skin draping and sagging]; Grade 3 (moderate): may have mild to moderate superficial wrinkling, skin has mild to moderate separation from deeper neck structures, moderate skin redundancy [moderate skin draping and skin sagging]; Grade 4 (severe): mild to marked superficial wrinkling, loose skin separated from deeper neck structures, marked skin redundancy [marked skin draping and sagging]. A negative change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1029</enrollment>
  <condition>Submental Fullness</condition>
  <arm_group>
    <arm_group_label>All Enrolled Participants</arm_group_label>
    <description>All enrolled participants who signed informed consent whether or not they elected to receive treatment as per standard of care in clinical practice for submental fat (SMF). Treatments for SMF included: ATX1-101, Surgical Procedures, Laser Liposuction, Energy Devices or Other Treatments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deoxycholic acid</intervention_name>
    <description>Deoxycholic acid (ATX-101) injection as the treatment of SMF as per standard of care in clinical practice.</description>
    <arm_group_label>All Enrolled Participants</arm_group_label>
    <other_name>ATX-101</other_name>
    <other_name>KYBELLA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical Procedures</intervention_name>
    <description>Surgical procedures for treatment of SMF as per standard of care in clinical practice.</description>
    <arm_group_label>All Enrolled Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laser Liposuction</intervention_name>
    <description>Laser Liposuction for the treatment of SMF as per standard of care in clinical practice..</description>
    <arm_group_label>All Enrolled Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Energy Devices</intervention_name>
    <description>Energy Devices for the treatment of SMF as per standard of care in clinical practice.</description>
    <arm_group_label>All Enrolled Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Other Treatments</intervention_name>
    <description>Other treatments for SMF as per standard of care in clinical practice.</description>
    <arm_group_label>All Enrolled Participants</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients considering treatment to reduce SMF will be recruited from practices that see a
        large number of aesthetic patients with a variety of issues, including SMF.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male and female patients, aged 18 years and above, presenting with SM fullness
             due to the accumulation of unwanted SMF, and considered by their treating physician to
             be a candidate to receive treatment of SM fullness by reduction of SMF, if the patient
             decides

          -  Signed informed consent by the patient, obtained before any study-related activities
             are undertaken

          -  Willing to complete all patient assessment questionnaires

          -  Signed release form by the patient, permitting abstraction of the patient's medical
             records at baseline and during participation in the registry

        Exclusion Criteria:

          -  Severe skin laxity, defined as superficial wrinkling, loose skin separated from deeper
             neck structures, and/or marked skin redundancy (draping and/or sagging), per the
             physician's judgment

          -  Any other cause of fullness in the SM area (eg, thyroid enlargement, cervical
             adenopathy) other than localized SMF

          -  Participating in an interventional clinical study, currently or within 30 days before
             enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rina Patel, MS, CCRA</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skin Spectrum LLC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Joseph, MD</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Roxbury Institute</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brian M Kinney, MD Inc</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bella Skin Institute</name>
      <address>
        <city>Calabasas</city>
        <state>California</state>
        <zip>91302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jerome R Potozkin MD</name>
      <address>
        <city>Danville</city>
        <state>California</state>
        <zip>94526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kathleen L Behr</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ocdermatology Lorrie Klein</name>
      <address>
        <city>Laguna Niguel</city>
        <state>California</state>
        <zip>92677</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westside Aesthetics</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Care and Laser Physicians of Beverly Hills</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Batniji Facial Plastic Surgery</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steve Yoelin, M.D. Medical Associates, Inc.</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teleos Plastic Surgery &amp;. Radiance Medical Group Inc</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laser And Skin Surgery Center Of Northern California</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Cosmetic Laser Medical Associates of La JollaInc</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FacesPlus</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Goldman Butterwick Fitzpatrick Groff And Fabi Cosmetic Laser</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Maas Clinic - San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115-1809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Area Cosmetic Dermatology Kathleen M Welsh Md</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vic A Narurkar MD APC</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grossman Dermatology</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Art Of Skin MD</name>
      <address>
        <city>Solana Beach</city>
        <state>California</state>
        <zip>92075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moradi Md</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice Dr Mary Lynn Moran</name>
      <address>
        <city>Woodside</city>
        <state>California</state>
        <zip>94062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AboutSkin Dermatology and Dermsurg</name>
      <address>
        <city>Greenwood Village</city>
        <state>Colorado</state>
        <zip>80111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wa Institute Dermatologic Laser Surg</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanctuary Medical Aesthetic Center</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steven Fagien, MD, PA</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Care Research, Inc</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Susan H Weinkle Md</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Research Institute</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146-1871</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Miami Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Dermatology and Laser Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center For Sight</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of the Southeast</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carmen Kavali</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Connors Plastic Surgery</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DeNova Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laser &amp; Skin Surgery Center of Indiana</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coleman Center For Cosmetic Dermatologic Surgery</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lupo Center for Aesthetic and General Dermatology</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facial Plastic Surgical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologic Surgery Center of Washington LLC</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Callender Center for Clinical Research, LLC</name>
      <address>
        <city>Glenn Dale</city>
        <state>Maryland</state>
        <zip>20769</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Laser Skin &amp; Vein Inst</name>
      <address>
        <city>Hunt Valley</city>
        <state>Maryland</state>
        <zip>21030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lawrence Green MD LLC</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ranella Hirsch</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Care Physicians</name>
      <address>
        <city>Chestnut Hill</city>
        <state>Massachusetts</state>
        <zip>02467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Partners</name>
      <address>
        <city>Wellesley</city>
        <state>Massachusetts</state>
        <zip>02481</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boyd</name>
      <address>
        <city>Birmingham</city>
        <state>Michigan</state>
        <zip>48009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Skin Specialists LTD</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Specialists, P.C.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice Dr Angela Beckford</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Image Dermatology P.C.</name>
      <address>
        <city>Montclair</city>
        <state>New Jersey</state>
        <zip>07042-3439</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Jersey Plastic Surgery</name>
      <address>
        <city>Montclair</city>
        <state>New Jersey</state>
        <zip>07042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Hills Dermatology Group</name>
      <address>
        <city>Forest Hills</city>
        <state>New York</state>
        <zip>11375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center For Dermatology Cosmetic And Laser Surgery</name>
      <address>
        <city>Mount Kisco</city>
        <state>New York</state>
        <zip>10549</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doris Day Pc</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Cosmetic, Skin and Laser Surgery Center (NYC)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JUVA Skin and Laser Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022-3350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marmur Medical</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Laser and Skin Care</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luxurgery NYC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sadick Research Group</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marina I Peredo M.D., P.C.</name>
      <address>
        <city>Smithtown</city>
        <state>New York</state>
        <zip>11787</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mariwalla Dermatology</name>
      <address>
        <city>West Islip</city>
        <state>New York</state>
        <zip>11795</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Finn Facial Plastics</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology, Laser &amp; Vein Specialists of the Carolinas</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilmington Dermatology Center</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health And Science University Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Main Line Center for Laser Surgery</name>
      <address>
        <city>Ardmore</city>
        <state>Pennsylvania</state>
        <zip>19003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Plaza Surgical Center</name>
      <address>
        <city>Bala-Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologic SurgiCenter</name>
      <address>
        <city>Drexel Hill</city>
        <state>Pennsylvania</state>
        <zip>19026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brian S. Biesman, M.D.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westlake Dermatology And Cosmetic Surgery</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78746</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellaire Dermatology Associates (BDA)</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401-3505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Clinical Research Center of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gateway Aesthetic Institute &amp; Laser Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hema A Sundaram MDPA</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naficy Plastic Surgery And Rejuvenation Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Jean Carruthers Cosmetic Surgey Inc.</name>
      <address>
        <city>Vancouver, B. C.</city>
        <state>British Columbia</state>
        <zip>V5Z 4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Shannon Humphrey, Inc.</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Dermaesthetics</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6E 4M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Project Skin Vancouver</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 1K9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North York General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M2K 1E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Research Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3H 5Y8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Dermatology</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4S 2N5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sweat Clinics of Canada</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5R3N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bertucci MedSpa, Inc.</name>
      <address>
        <city>Woodbridge</city>
        <state>Ontario</state>
        <zip>L4L 8E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medime Institut de medecine esthetique</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3S2W1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Nikolis</name>
      <address>
        <city>Mount Royal</city>
        <state>Quebec</state>
        <zip>H3R 3A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>May 6, 2015</study_first_submitted>
  <study_first_submitted_qc>May 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2015</study_first_posted>
  <results_first_submitted>November 14, 2017</results_first_submitted>
  <results_first_submitted_qc>October 4, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 5, 2018</results_first_posted>
  <last_update_submitted>October 4, 2018</last_update_submitted>
  <last_update_submitted_qc>October 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deoxycholic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Enrolled Participants</title>
          <description>All enrolled participants who signed informed consent whether or not they elected to receive treatment as per standard of care in clinical practice for submental fat (SMF). Treatments for SMF included: ATX1-101, Surgical Procedures, Laser Liposuction, Energy Devices or Other Treatments.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1029"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment for SMF</title>
              <participants_list>
                <participants group_id="P1" count="676"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Did Not ReceiveTreatment for SMF</title>
              <participants_list>
                <participants group_id="P1" count="353"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="504"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="525"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Patient Decision</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Lost to Follow-Up</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Ended by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patients Not Treated/No EOT Visit</title>
              <participants_list>
                <participants group_id="P1" count="249"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Enrolled Participants include all participants who signed informed consent whether or not they elected to receive treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>All Enrolled Participants</title>
          <description>All enrolled participants who signed informed consent whether or not they elected to receive treatment as per standard of care in clinical practice for submental fat (SMF). Treatments for SMF included: ATX1-101, Surgical Procedures, Laser Liposuction, Energy Devices or Other Treatments.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1029"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.9" spread="12.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18 to 30 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>31 to 50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>51 to 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="883"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)</title>
        <description>An adverse event is any undesirable medical occurrence or worsening of an existing condition that occurs after SMF reduction treatment, irrespective of whether the event is considered treatment related. A treatment-emergent adverse event is defined as an adverse event with an onset that occurs after receiving treatment.</description>
        <time_frame>Up to 19 Months</time_frame>
        <population>Safety Population included all participants who received at least one treatment. Participants may have received more than one treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Deoxycholic Acid (ATX-101)</title>
            <description>Deoxycholic acid injection (ATX-101) as treatment for SMF as per standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Surgical</title>
            <description>Surgical procedures for the treatment of SMF as per standard of care in clinical practice.</description>
          </group>
          <group group_id="O3">
            <title>Laser Liposuction</title>
            <description>Laser Liposuction for treatment of SMF as per standard of care in clinical practice.</description>
          </group>
          <group group_id="O4">
            <title>Energy Devices</title>
            <description>Energy Devices as treatment for SMF as per standard of care in clinical practice.</description>
          </group>
          <group group_id="O5">
            <title>Other Treatments</title>
            <description>Other Treatments for treatment of SMF as per standard of care in clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)</title>
          <description>An adverse event is any undesirable medical occurrence or worsening of an existing condition that occurs after SMF reduction treatment, irrespective of whether the event is considered treatment related. A treatment-emergent adverse event is defined as an adverse event with an onset that occurs after receiving treatment.</description>
          <population>Safety Population included all participants who received at least one treatment. Participants may have received more than one treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="570"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2"/>
                    <measurement group_id="O2" value="8.7"/>
                    <measurement group_id="O3" value="20.0"/>
                    <measurement group_id="O4" value="5.2"/>
                    <measurement group_id="O5" value="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)</title>
        <description>The CR-SMFRS is based on the investigator's clinical evaluation of the participant's chin and neck area using a 5-point ordinal scale (0 to 4) with 0=Absent Submental Convexity: no localized submental fat evident; 1=Mild Submental Convexity: minimal, localized submental fat; 2=Moderate Submental Convexity: prominent, localized submental fat; 3=Severe Submental Convexity; a marked amount of chin fat; and 4=Extreme Submental Convexity: marked, localized submental fat. A negative change from Baseline indicates improvement.</description>
        <time_frame>Baseline (Day 1) to the Follow-up Visit (Up to 9 Months) and Baseline to End of Treatment (EOT) Visit (Up to 18 Months)</time_frame>
        <population>Full Analysis Set included all enrolled participants with a baseline visit and at least one post-baseline visit. Participants may have received more than one treatment. Number analyzed is the number of participants with data available for this outcome measure at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Deoxycholic Acid (ATX-101)</title>
            <description>Deoxycholic acid injection (ATX-101) as treatment for SMF as per standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Surgical</title>
            <description>Surgical procedures for the treatment of SMF as per standard of care in clinical practice.</description>
          </group>
          <group group_id="O3">
            <title>Laser Liposuction</title>
            <description>Laser Liposuction for treatment of SMF as per standard of care in clinical practice.</description>
          </group>
          <group group_id="O4">
            <title>Energy Devices</title>
            <description>Energy Devices as treatment for SMF as per standard of care in clinical practice.</description>
          </group>
          <group group_id="O5">
            <title>Other Treatments</title>
            <description>Other Treatments for treatment of SMF as per standard of care in clinical practice.</description>
          </group>
          <group group_id="O6">
            <title>Not Elected Treatment</title>
            <description>All enrolled participants who did not elect to have treatment for SMF.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)</title>
          <description>The CR-SMFRS is based on the investigator's clinical evaluation of the participant's chin and neck area using a 5-point ordinal scale (0 to 4) with 0=Absent Submental Convexity: no localized submental fat evident; 1=Mild Submental Convexity: minimal, localized submental fat; 2=Moderate Submental Convexity: prominent, localized submental fat; 3=Severe Submental Convexity; a marked amount of chin fat; and 4=Extreme Submental Convexity: marked, localized submental fat. A negative change from Baseline indicates improvement.</description>
          <population>Full Analysis Set included all enrolled participants with a baseline visit and at least one post-baseline visit. Participants may have received more than one treatment. Number analyzed is the number of participants with data available for this outcome measure at the given time-point.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="570"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="676"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="568"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="77"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="674"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="0.8"/>
                    <measurement group_id="O2" value="2.7" spread="0.8"/>
                    <measurement group_id="O3" value="3.2" spread="0.8"/>
                    <measurement group_id="O4" value="1.7" spread="0.8"/>
                    <measurement group_id="O5" value="1.8" spread="1.1"/>
                    <measurement group_id="O6" value="2.0" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Follow-up Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="406"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="49"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="483"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.7"/>
                    <measurement group_id="O2" value="-1.6" spread="1.1"/>
                    <measurement group_id="O3" value="-2.0" spread="1.0"/>
                    <measurement group_id="O4" value="-0.7" spread="0.7"/>
                    <measurement group_id="O5" value="-0.4" spread="0.6"/>
                    <measurement group_id="O6" value="-0.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to EOT Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="379"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="49"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="449"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.8"/>
                    <measurement group_id="O2" value="-2.1" spread="1.0"/>
                    <measurement group_id="O3" value="-2.5" spread="0.7"/>
                    <measurement group_id="O4" value="-0.9" spread="1.0"/>
                    <measurement group_id="O5" value="-0.2" spread="0.5"/>
                    <measurement group_id="O6" value="-0.8" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient-Reported Submental Fat Rating Scale (PR-SMFRS)</title>
        <description>The PR-SMFRS is based on the participant's response to the question &quot;How much fat do you have under your chin right now?&quot; answered on a 5-point ordinal scale (0 to 4) with 0=No chin fat at all, 1=A slight amount of chin fat, 2=A moderate amount of chin fat, 3=A large amount of chin fat, and 4=A very large amount of chin fat. A negative change from Baseline indicates improvement.</description>
        <time_frame>Baseline (Day 1) to the Follow-up Visit (Up to 9 Months) and Baseline to End of Treatment Visit (Up to 18 Months)</time_frame>
        <population>Full Analysis Set included all enrolled participants with a baseline visit and at least one post-baseline visit. Participants may have received more than one treatment. Number analyzed is the number of participants with data available for this outcome measure at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Deoxycholic Acid (ATX-101)</title>
            <description>Deoxycholic acid injection (ATX-101) as treatment for SMF as per standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Surgical</title>
            <description>Surgical procedures for the treatment of SMF as per standard of care in clinical practice.</description>
          </group>
          <group group_id="O3">
            <title>Laser Liposuction</title>
            <description>Laser Liposuction for treatment of SMF as per standard of care in clinical practice.</description>
          </group>
          <group group_id="O4">
            <title>Energy Devices</title>
            <description>Energy Devices as treatment for SMF as per standard of care in clinical practice.</description>
          </group>
          <group group_id="O5">
            <title>Other Treatments</title>
            <description>Other Treatments for treatment of SMF as per standard of care in clinical practice.</description>
          </group>
          <group group_id="O6">
            <title>Not Elected Treatment</title>
            <description>All enrolled participants who did not elect to have treatment for SMF.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient-Reported Submental Fat Rating Scale (PR-SMFRS)</title>
          <description>The PR-SMFRS is based on the participant's response to the question &quot;How much fat do you have under your chin right now?&quot; answered on a 5-point ordinal scale (0 to 4) with 0=No chin fat at all, 1=A slight amount of chin fat, 2=A moderate amount of chin fat, 3=A large amount of chin fat, and 4=A very large amount of chin fat. A negative change from Baseline indicates improvement.</description>
          <population>Full Analysis Set included all enrolled participants with a baseline visit and at least one post-baseline visit. Participants may have received more than one treatment. Number analyzed is the number of participants with data available for this outcome measure at the given time-point.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="570"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="676"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="568"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="77"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="674"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="0.7"/>
                    <measurement group_id="O2" value="2.5" spread="0.7"/>
                    <measurement group_id="O3" value="3.2" spread="0.8"/>
                    <measurement group_id="O4" value="1.8" spread="0.7"/>
                    <measurement group_id="O5" value="2.0" spread="0.9"/>
                    <measurement group_id="O6" value="2.0" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Follow-up Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="409"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="485"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.7"/>
                    <measurement group_id="O2" value="-1.5" spread="0.9"/>
                    <measurement group_id="O3" value="-2.2" spread="1.1"/>
                    <measurement group_id="O4" value="-0.5" spread="0.8"/>
                    <measurement group_id="O5" value="-0.8" spread="0.8"/>
                    <measurement group_id="O6" value="-0.4" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to EOT Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="383"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="49"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="452"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.8"/>
                    <measurement group_id="O2" value="-1.6" spread="0.9"/>
                    <measurement group_id="O3" value="-2.0" spread="0.0"/>
                    <measurement group_id="O4" value="-0.8" spread="0.9"/>
                    <measurement group_id="O5" value="-0.5" spread="0.6"/>
                    <measurement group_id="O6" value="-0.7" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Patient-Reported Submental Fat Impact Scale (PR-SMFIS)</title>
        <description>The PR-SMFIS assesses the impact of submental fat on self-perception of 6 emotional and visual characteristics related to the appearance of submental fullness (unhappy, bothered, self-conscious, embarrassed, look older, and look overweight) as evaluated by the participant. Each item is rated on an 11-point numeric scale from 0 to 10. Scores for the 6 items were averaged to generate a PR-SMFIS total scale score ranging from 0 to 10 where 0 is a positive outcome and 10 is a negative outcome. A negative change from Baseline indicates improvement.</description>
        <time_frame>Baseline (Day 1) to the Follow-up Visit (Up to 9 Months) and Baseline to End of Treatment Visit (Up to 18 Months)</time_frame>
        <population>Full Analysis Set included all enrolled participants with a baseline visit and at least one post-baseline visit. Participants may have received more than one treatment. Number analyzed is the number of participants with data available for this outcome measure at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Deoxycholic Acid (ATX-101)</title>
            <description>Deoxycholic acid injection (ATX-101) as treatment for SMF as per standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Surgical</title>
            <description>Surgical procedures for the treatment of SMF as per standard of care in clinical practice.</description>
          </group>
          <group group_id="O3">
            <title>Laser Liposuction</title>
            <description>Laser Liposuction for treatment of SMF as per standard of care in clinical practice.</description>
          </group>
          <group group_id="O4">
            <title>Energy Devices</title>
            <description>Energy Devices as treatment for SMF as per standard of care in clinical practice.</description>
          </group>
          <group group_id="O5">
            <title>Other Treatments</title>
            <description>Other Treatments for treatment of SMF as per standard of care in clinical practice.</description>
          </group>
          <group group_id="O6">
            <title>Not Elected Treatment</title>
            <description>All enrolled participants who did not elect to have treatment for SMF.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Patient-Reported Submental Fat Impact Scale (PR-SMFIS)</title>
          <description>The PR-SMFIS assesses the impact of submental fat on self-perception of 6 emotional and visual characteristics related to the appearance of submental fullness (unhappy, bothered, self-conscious, embarrassed, look older, and look overweight) as evaluated by the participant. Each item is rated on an 11-point numeric scale from 0 to 10. Scores for the 6 items were averaged to generate a PR-SMFIS total scale score ranging from 0 to 10 where 0 is a positive outcome and 10 is a negative outcome. A negative change from Baseline indicates improvement.</description>
          <population>Full Analysis Set included all enrolled participants with a baseline visit and at least one post-baseline visit. Participants may have received more than one treatment. Number analyzed is the number of participants with data available for this outcome measure at the given time-point.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="570"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="676"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="569"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="77"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="675"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="1.8"/>
                    <measurement group_id="O2" value="7.9" spread="1.5"/>
                    <measurement group_id="O3" value="9.0" spread="0.0"/>
                    <measurement group_id="O4" value="6.2" spread="2.2"/>
                    <measurement group_id="O5" value="7.0" spread="2.4"/>
                    <measurement group_id="O6" value="6.9" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Follow-up Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="408"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="484"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="1.9"/>
                    <measurement group_id="O2" value="-4.6" spread="2.3"/>
                    <measurement group_id="O3" value="-6.6" spread="2.7"/>
                    <measurement group_id="O4" value="-1.8" spread="2.4"/>
                    <measurement group_id="O5" value="-2.4" spread="2.1"/>
                    <measurement group_id="O6" value="-1.5" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to EOT Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="382"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="49"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="451"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="2.6"/>
                    <measurement group_id="O2" value="-5.4" spread="2.6"/>
                    <measurement group_id="O3" value="-6.5" spread="2.1"/>
                    <measurement group_id="O4" value="-2.4" spread="2.7"/>
                    <measurement group_id="O5" value="-2.3" spread="1.3"/>
                    <measurement group_id="O6" value="-2.9" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Subject Self Rating Scale (SSRS)</title>
        <description>The participant was asked to answer the question: &quot;Considering your appearance in association with your face and chin, how satisfied do you feel with your appearance at the present time?&quot; using a 7-point scale: 0=Extremely dissatisfied, 1=Dissatisfied, 2=Slightly dissatisfied, 3=neither satisfied nor dissatisfied, 4=Slightly satisfied, 5=Satisfied, and 6=Extremely satisfied. A positive change from Baseline indicates improvement.</description>
        <time_frame>Baseline (Day 1) to the Follow-up Visit (Up to 9 Months) and Baseline to End of Treatment Visit (Up to 18 Months)</time_frame>
        <population>Full Analysis Set included all enrolled participants with a baseline visit and at least one post-baseline visit. Participants may have received more than one treatment. Number analyzed is the number of participants with data available for this outcome measure at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Deoxycholic Acid (ATX-101)</title>
            <description>Deoxycholic acid injection (ATX-101) as treatment for SMF as per standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Surgical</title>
            <description>Surgical procedures for the treatment of SMF as per standard of care in clinical practice.</description>
          </group>
          <group group_id="O3">
            <title>Laser Liposuction</title>
            <description>Laser Liposuction for treatment of SMF as per standard of care in clinical practice.</description>
          </group>
          <group group_id="O4">
            <title>Energy Devices</title>
            <description>Energy Devices as treatment for SMF as per standard of care in clinical practice.</description>
          </group>
          <group group_id="O5">
            <title>Other Treatments</title>
            <description>Other Treatments for treatment of SMF as per standard of care in clinical practice.</description>
          </group>
          <group group_id="O6">
            <title>Not Elected Treatment</title>
            <description>All enrolled participants who did not elect to have treatment for SMF.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Subject Self Rating Scale (SSRS)</title>
          <description>The participant was asked to answer the question: &quot;Considering your appearance in association with your face and chin, how satisfied do you feel with your appearance at the present time?&quot; using a 7-point scale: 0=Extremely dissatisfied, 1=Dissatisfied, 2=Slightly dissatisfied, 3=neither satisfied nor dissatisfied, 4=Slightly satisfied, 5=Satisfied, and 6=Extremely satisfied. A positive change from Baseline indicates improvement.</description>
          <population>Full Analysis Set included all enrolled participants with a baseline visit and at least one post-baseline visit. Participants may have received more than one treatment. Number analyzed is the number of participants with data available for this outcome measure at the given time-point.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="570"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="676"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="569"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="77"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="675"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="1.4"/>
                    <measurement group_id="O2" value="2.0" spread="1.6"/>
                    <measurement group_id="O3" value="1.4" spread="1.5"/>
                    <measurement group_id="O4" value="2.1" spread="1.4"/>
                    <measurement group_id="O5" value="2.6" spread="1.2"/>
                    <measurement group_id="O6" value="2.2" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Follow-up Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="407"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="483"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.7"/>
                    <measurement group_id="O2" value="2.4" spread="1.9"/>
                    <measurement group_id="O3" value="3.6" spread="2.1"/>
                    <measurement group_id="O4" value="1.6" spread="1.8"/>
                    <measurement group_id="O5" value="1.2" spread="2.2"/>
                    <measurement group_id="O6" value="1.1" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="382"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="49"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="451"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="2.0"/>
                    <measurement group_id="O2" value="2.8" spread="2.3"/>
                    <measurement group_id="O3" value="4.5" spread="2.1"/>
                    <measurement group_id="O4" value="2.1" spread="1.9"/>
                    <measurement group_id="O5" value="1.3" spread="1.5"/>
                    <measurement group_id="O6" value="2.1" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Patient Self-Perception of Age (SPA)</title>
        <description>The participant rated their facial age in years at Baseline and at the End of Treatment Visit by answering the question: How many years difference compare to your actual age? A negative number indicates younger and a positive number indicates older. A negative change from Baseline indicates an improvement.</description>
        <time_frame>Baseline (Day 1) to End of Treatment Visit (Up to 18 Months)</time_frame>
        <population>Full Analysis Set included all enrolled participants with a baseline visit and at least one post-baseline visit. Participants may have received more than one treatment. Number analyzed is the number of participants with data available for this outcome measure at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Deoxycholic Acid (ATX-101)</title>
            <description>Deoxycholic acid injection (ATX-101) as treatment for SMF as per standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Surgical</title>
            <description>Surgical procedures for the treatment of SMF as per standard of care in clinical practice.</description>
          </group>
          <group group_id="O3">
            <title>Laser Liposuction</title>
            <description>Laser Liposuction for treatment of SMF as per standard of care in clinical practice.</description>
          </group>
          <group group_id="O4">
            <title>Energy Devices</title>
            <description>Energy Devices as treatment for SMF as per standard of care in clinical practice.</description>
          </group>
          <group group_id="O5">
            <title>Other Treatments</title>
            <description>Other Treatments for treatment of SMF as per standard of care in clinical practice.</description>
          </group>
          <group group_id="O6">
            <title>Not Elected Treatment</title>
            <description>All enrolled participants who did not elect to have treatment for SMF.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Patient Self-Perception of Age (SPA)</title>
          <description>The participant rated their facial age in years at Baseline and at the End of Treatment Visit by answering the question: How many years difference compare to your actual age? A negative number indicates younger and a positive number indicates older. A negative change from Baseline indicates an improvement.</description>
          <population>Full Analysis Set included all enrolled participants with a baseline visit and at least one post-baseline visit. Participants may have received more than one treatment. Number analyzed is the number of participants with data available for this outcome measure at the given time-point.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="570"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="676"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="569"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="77"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="675"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="5.0"/>
                    <measurement group_id="O2" value="0.5" spread="4.3"/>
                    <measurement group_id="O3" value="3.0" spread="6.7"/>
                    <measurement group_id="O4" value="-0.5" spread="4.1"/>
                    <measurement group_id="O5" value="-0.6" spread="3.2"/>
                    <measurement group_id="O6" value="-1.2" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to EOT Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="382"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="49"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="451"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="5.3"/>
                    <measurement group_id="O2" value="-5.6" spread="6.2"/>
                    <measurement group_id="O3" value="-10.0" spread="0.0"/>
                    <measurement group_id="O4" value="-0.6" spread="3.1"/>
                    <measurement group_id="O5" value="-0.8" spread="4.4"/>
                    <measurement group_id="O6" value="-1.6" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Submental Skin Laxity Scale (SMSLG)</title>
        <description>SMSLG assessment was based on clinical evaluation and palpation of the submental area. The SMSLG scale incorporates 3 features: skin wrinkling, adherence to underlying neck structures (bone and muscle) and redundancy (horizontal and vertical folds).
Grade 1 (none): no or minimal superficial wrinkling, skin well apposed to deeper neck structures, no skin redundancy [no skin draping or skin sagging]; Grade 2 (mild): mild superficial wrinkling, skin well apposed to deeper neck structures, minimal skin redundancy [slight skin draping and sagging]; Grade 3 (moderate): may have mild to moderate superficial wrinkling, skin has mild to moderate separation from deeper neck structures, moderate skin redundancy [moderate skin draping and skin sagging]; Grade 4 (severe): mild to marked superficial wrinkling, loose skin separated from deeper neck structures, marked skin redundancy [marked skin draping and sagging]. A negative change from Baseline indicates improvement.</description>
        <time_frame>Baseline (Day 1) to the Follow-up Visit (Up to 9 Months) and Baseline to End of Treatment Visit (Up to 18 Months)</time_frame>
        <population>Full Analysis Set included all enrolled participants with a baseline visit and at least one post-baseline visit. Participants may have received more than one treatment. Number analyzed is the number of participants with data available for this outcome measure at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Deoxycholic Acid (ATX-101)</title>
            <description>Deoxycholic acid injection (ATX-101) as treatment for SMF as per standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Surgical</title>
            <description>Surgical procedures for the treatment of SMF as per standard of care in clinical practice.</description>
          </group>
          <group group_id="O3">
            <title>Laser Liposuction</title>
            <description>Laser Liposuction for treatment of SMF as per standard of care in clinical practice.</description>
          </group>
          <group group_id="O4">
            <title>Energy Devices</title>
            <description>Energy Devices as treatment for SMF as per standard of care in clinical practice.</description>
          </group>
          <group group_id="O5">
            <title>Other Treatments</title>
            <description>Other Treatments for treatment of SMF as per standard of care in clinical practice.</description>
          </group>
          <group group_id="O6">
            <title>Not Elected Treatment</title>
            <description>All enrolled participants who did not elect to have treatment for SMF.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Submental Skin Laxity Scale (SMSLG)</title>
          <description>SMSLG assessment was based on clinical evaluation and palpation of the submental area. The SMSLG scale incorporates 3 features: skin wrinkling, adherence to underlying neck structures (bone and muscle) and redundancy (horizontal and vertical folds).
Grade 1 (none): no or minimal superficial wrinkling, skin well apposed to deeper neck structures, no skin redundancy [no skin draping or skin sagging]; Grade 2 (mild): mild superficial wrinkling, skin well apposed to deeper neck structures, minimal skin redundancy [slight skin draping and sagging]; Grade 3 (moderate): may have mild to moderate superficial wrinkling, skin has mild to moderate separation from deeper neck structures, moderate skin redundancy [moderate skin draping and skin sagging]; Grade 4 (severe): mild to marked superficial wrinkling, loose skin separated from deeper neck structures, marked skin redundancy [marked skin draping and sagging]. A negative change from Baseline indicates improvement.</description>
          <population>Full Analysis Set included all enrolled participants with a baseline visit and at least one post-baseline visit. Participants may have received more than one treatment. Number analyzed is the number of participants with data available for this outcome measure at the given time-point.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="570"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="676"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="569"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="77"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="675"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="0.8"/>
                    <measurement group_id="O2" value="2.2" spread="0.7"/>
                    <measurement group_id="O3" value="2.0" spread="0.7"/>
                    <measurement group_id="O4" value="2.1" spread="0.8"/>
                    <measurement group_id="O5" value="2.0" spread="0.7"/>
                    <measurement group_id="O6" value="2.0" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Follow-up Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="405"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="49"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="482"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.7"/>
                    <measurement group_id="O2" value="-0.6" spread="1.0"/>
                    <measurement group_id="O3" value="-0.4" spread="1.1"/>
                    <measurement group_id="O4" value="-0.4" spread="0.6"/>
                    <measurement group_id="O5" value="-0.4" spread="0.6"/>
                    <measurement group_id="O6" value="-0.2" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to EOT Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="378"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="49"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="448"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.7"/>
                    <measurement group_id="O2" value="-0.6" spread="1.0"/>
                    <measurement group_id="O3" value="-0.5" spread="0.7"/>
                    <measurement group_id="O4" value="-0.3" spread="0.6"/>
                    <measurement group_id="O5" value="-0.2" spread="0.5"/>
                    <measurement group_id="O6" value="-0.3" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 19 Months</time_frame>
      <desc>Safety Population included all participants who received at least one treatment. Participants may have received more than one treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Deoxycholic Acid (ATX-101)</title>
          <description>Deoxycholic acid injection (ATX-101) as treatment for SMF as per standard of care.</description>
        </group>
        <group group_id="E2">
          <title>Surgical</title>
          <description>Surgical procedures for the treatment of SMF as per standard of care in clinical practice.</description>
        </group>
        <group group_id="E3">
          <title>Laser Liposuction</title>
          <description>Laser Liposuction for treatment of SMF as per standard of care in clinical practice.</description>
        </group>
        <group group_id="E4">
          <title>Energy Devices</title>
          <description>Energy Devices as treatment for SMF as per standard of care in clinical practice.</description>
        </group>
        <group group_id="E5">
          <title>Other Treatments</title>
          <description>Other Treatments for treatment of SMF as per standard of care in clinical practice.</description>
        </group>
        <group group_id="E6">
          <title>All Treated Participants</title>
          <description>All participants who received treatment for SMF as per standard of care in clinical practice: ATX1-101, Surgical Procedures, Laser Liposuction, Energy Devices or Other Treatments.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="676"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="81" subjects_at_risk="676"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="676"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="63" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Injection site hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="39" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="38" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Injection site nodule</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Application site ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Injection site oedema</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Injection site discomfort</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Injection site nerve damage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Injection site paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Injection site scab</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Uncoded</sub_title>
                <description>Uncoded</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="676"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cutaneous symptom</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="676"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="676"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Institution and/or Investigator shall allow Sponsor not less than 45 days to review any manuscript and not less than 30 days to review any poster presentation, abstract or any other written or oral material which describes or discloses the Study results. Institution and Investigator agree that because the Study is part of a multi-center Study, any publication by Institution or Investigator of the Study Results shall not be made before the first multi-center publication of participating sites.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director/ Epidemiologist</name_or_title>
      <organization>Allergan, Inc</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

